Trial Profile
A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- Acronyms HEART
- 28 Feb 2017 New trial record